3-Deazaadenosine: Potent SAH Hydrolase Inhibitor for Methylation and Antiviral Research

Executive Summary: 3-Deazaadenosine is a potent inhibitor of S-adenosylhomocysteine (SAH) hydrolase (Ki = 3.9 μM), directly elevating intracellular SAH and altering the SAH-to-SAM ratio, which suppresses methyltransferase-dependent processes (APExBIO). Its activity has been validated in both methylation research and preclinical antiviral models, including Ebola virus systems (Wu et al., 2024). The compound demonstrates robust in vitro and in vivo efficacy, with defined solubility and stability parameters. APExBIO offers 3-Deazaadenosine (SKU: B6121) as a reference-grade reagent. Recent findings connect 3-Deazaadenosine-mediated methylation inhibition to epigenetic regulation in inflammatory and infectious disease models.

Biological Rationale

3-Deazaadenosine targets S-adenosylhomocysteine (SAH) hydrolase, an enzyme that catalyzes the reversible hydrolysis of SAH into adenosine and homocysteine. SAH is a potent competitive inhibitor of S-adenosylmethionine (SAM)-dependent methyltransferases. Elevation of intracellular SAH, by inhibiting SAH hydrolase, results in the suppression of methylation reactions, including those involved in epigenetic regulation and RNA modification (APExBIO). This molecular mechanism is central to understanding the compound’s impact on cellular metabolism, gene expression, and viral replication.

Recent studies emphasize the role of methylation, specifically N6-methyladenosine (m6A) RNA modification, in inflammatory diseases such as ulcerative colitis (UC), where methyltransferase-like 14 (METTL14) exerts regulatory effects on non-coding RNA and cytokine expression (Wu et al., 2024). By modulating methyltransferase activity, 3-Deazaadenosine provides a tool to dissect the functional outcomes of methylation in both health and disease. This article extends prior overviews of 3-Deazaadenosine’s methylation research utility by focusing on new epigenetic and antiviral evidence.

Mechanism of Action of 3-Deazaadenosine

3-Deazaadenosine is a structural analog of adenosine that binds and inhibits SAH hydrolase, resulting in the accumulation of SAH inside the cell. The increased SAH/SAM ratio competitively inhibits SAM-dependent methyltransferases, including DNA, RNA, and protein methyltransferases. This leads to global hypomethylation of nucleic acids and proteins, modulating gene expression and interfering with viral RNA cap methylation—a process critical for viral replication (see strategic guidance).

The Ki for SAH hydrolase inhibition by 3-Deazaadenosine is 3.9 μM, as determined in enzymatic assays at physiological pH and temperature (APExBIO). Inhibition of methyltransferases downstream of SAH accumulation affects m6A RNA modifications, which are dynamically regulated by writer enzymes such as METTL3/METTL14 and are implicated in inflammation and viral pathogenesis (Wu et al., 2024).

Evidence & Benchmarks

• 3-Deazaadenosine inhibits SAH hydrolase with a Ki of 3.9 μM, elevating SAH and suppressing methyltransferase activity in vitro (APExBIO).
• In preclinical studies, 3-Deazaadenosine reduces m6A RNA methylation, impacting the expression of inflammatory mediators such as IL-1β, IL-6, TNF-α, and IFN-γ in cell and murine colitis models (Wu et al., 2024).
• It demonstrates potent antiviral activity against Ebola and Marburg viruses in primate and mouse cell lines, and provides protective efficacy in animal models of lethal Ebola infection (Mechanistic Leverage Article).
• Solubility benchmarks: ≥26.6 mg/mL in DMSO and ≥7.53 mg/mL in water with gentle warming; insoluble in ethanol (APExBIO).
• Stable as a solid at -20°C; solutions recommended for short-term use due to hydrolysis risk (APExBIO).

Compared to other mechanistic insights, this article highlights new evidence linking 3-Deazaadenosine’s methylation inhibition to inflammatory and antiviral models, updating prior benchmarks.

Applications, Limits & Misconceptions

3-Deazaadenosine is widely used in preclinical research to interrogate methylation-dependent pathways, including epigenetic regulation, inflammation, and viral infection mechanisms. It is a reference compound for dissecting m6A modification roles via inhibition of METTL3/METTL14-dependent methylation. The product also serves as a critical tool in antiviral research, especially for filoviruses such as Ebola, where methylation of viral RNA is essential for replication (see application benchmarks). This article expands on the translational implications previously summarized, providing updated parameters for experimental design.

Common Pitfalls or Misconceptions

• 3-Deazaadenosine is not selective for a specific methyltransferase; it inhibits all SAM-dependent methyltransferases via SAH accumulation.
• It does not directly inhibit METTL14 or METTL3, but affects them by altering cellular methylation substrate availability.
• The compound is unsuitable for use in ethanol-based solutions due to insolubility; DMSO or water with warming is required (APExBIO).
• Long-term storage of solutions leads to degradation; only fresh solutions should be used for reproducibility.
• It is not a therapeutic drug for clinical use; all applications are restricted to preclinical or research settings.

Workflow Integration & Parameters

For in vitro applications, 3-Deazaadenosine is typically dissolved in DMSO at concentrations up to 26.6 mg/mL, or in water (with gentle warming) up to 7.53 mg/mL. Working dilutions in culture media should not exceed 0.5% DMSO to avoid cytotoxicity. For in vivo animal studies, dosing regimens are based on prior benchmarks in Ebola virus disease models, with solution preparation occurring immediately before administration to ensure stability. The product's molecular weight is 266.25 (C11H14N4O4), facilitating accurate molar dosing. Storage at -20°C as a solid is recommended; solutions should be freshly prepared (APExBIO).

Conclusion & Outlook

3-Deazaadenosine (B6121, APExBIO) is a rigorously characterized SAH hydrolase inhibitor for research on methylation, epigenetic regulation, and antiviral mechanisms. Its robust activity in preclinical models underscores its status as a reference reagent. Future directions include leveraging its broad methylation inhibition profile to dissect m6A-mediated pathways in emerging disease models. For detailed protocols and ordering, consult the product page.